Listed by the USPTO as REGA, KYLE THOMAS
Tech Center 1600 • Art Units: 1636
This examiner grants 63% of resolved cases
REGA, KYLE THOMAS is assigned to tech center 1600 and art unit 1636. The record contains 119 resolved cases, a 63.0% allowance rate, and a median of 1292 days to allowance. The interview lift is 41.7%, indicating a substantial association between interviews and improved allowance outcomes in this record.
The leading companies are Research Institute At Nationwide Children's Hospital, Intellia Therapeutics Inc., and Howard Hughes Medical Institute. The principal firms are Leason Ellis LLP, MARSHALL, GERSTEIN & BORUN LLP, and MYERS BIGEL, P.A. Because the resolved-case volume is limited, counsel should use the profile as a focused guide rather than a complete predictor. The interview signal supports early preparation, while the 1292-day median calls for realistic timing and continuation planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17290317 | Split CPF1 Protein | Non-Final OA | The University of Tokyo |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.0% of resolved applications examined by Kyle Thomas Rega were allowed (119 resolved cases), compared with 37.1% across Art Unit 1636 over the last five years.
This examiner's interview lift is +41.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kyle Thomas Rega took 1,292 days on average from filing to allowance.
Kyle Thomas Rega examines applications in Art Unit 1636 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
